Biogen pushing tau drug forward despite Alzheimer’s study failure

An article from

Dive Brief

One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.

Published May 14, 2026

Biogen pushing tau drug forward despite Alzheimer’s study failure

Other newsrooms on this story

Related reading

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Updated: Biogen won’t be ‘impulsive’ with anti-tau Alzheimer’s drug

Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study

Stifel upgrades biotech stock on a narrative shift in Alzheimer’s treatment

Axsome wins FDA nod for Alzheimer's agitation

Eisai's slow push toward blockbuster Leqembi sales gains steam with $900M…